NCT05853198View on ClinicalTrials.gov

Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability

NARecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
OTHER

ctDNA analysis

ctDNA amount and mutations analysis

Trial Locations (1)

37134

RECRUITING

AOUI Verona, Verona

All Listed Sponsors
lead

Azienda Ospedaliera Universitaria Integrata Verona

OTHER